Last reviewed · How we verify
NCT04662346
Evaluation of Difficulty Score for Robotic Pancreatoduodenectomy
NA trial testing Difficulty score system for robotic pancreatoduodenectomy in Pancreatic Neoplasm in 1,000 participants. Status unknown.
20 January 2021
Quick facts
| Lead sponsor | University of Pisa |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 1,000 |
| Start date | 1 December 2020 |
| Primary completion | 20 January 2021 |
| Estimated completion | 28 February 2021 |
| Sites | 2 locations across Italy |
Drugs / interventions tested
- Difficulty score system for robotic pancreatoduodenectomy
Conditions studied
- Pancreatic Neoplasm — all drugs for Pancreatic Neoplasm →
Sponsor
University of Pisa
Who can join
Eligibility, any sex, with Pancreatic Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Robotic pancreatoduodenectomy is the most complex surgery for a general surgeon and consequently a pancreatic surgeon can aspire to. Due to the close proximity of the pancreas to the large vessels, great skill and experience in the field of pancreatic surgery, robotic surgery and also vascular surgery is essential. The ability to predict the depth of robotic pancreatoduodenectomy in each individual patient would be extremely important, for patient selection and for the implementation of the learning curve. This study aims to provide a difficulty score (DS) for robotic pancreatoduodenectomy to be used to select cases based on the experience and expertise of the surgeon.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The PD-ROBOSCORE: A difficulty score for robotic pancreatoduodenectomy.
Napoli N, Cacace C, Kauffmann EF, Jones L, et al · · 2023 · cited 27× · PMID 36973127 · DOI 10.1016/j.surg.2023.02.020
Verify or expand the search:
- PubMed search for NCT04662346
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Neoplasm
Currently open trials in the same condition.
- NCT06807437 — Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula · Phase 3 · recruiting
- NCT05687123 — Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors · Phase 1 · recruiting
- NCT06122896 — Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals · EARLY_PHASE1 · recruiting
- NCT06411795 — Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatodu · Phase 2 · recruiting
- NCT05961982 — Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study · NA · recruiting
Other University of Pisa trials
Trials by the same sponsor.
- NCT07520890 — Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs) · recruiting
- NCT07444229 — Team-Based Learning Integrated Into Clinical Simulation in Nursing Students · NA · not yet recruiting
- NCT07041983 — 24-h Energy Expenditure and Anti-obesity Medication · enrolling by invitation
- NCT07510685 — Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial) · NA · completed
- NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04662346 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pisa
- Last refreshed: 10 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04662346.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing